---

Low Dose Oral Interferon Alpha Our Lead Product Candidate
Low-dose oral interferon alpha is our therapeutic in the most advanced stage of clinical trials. Interferon alpha is a naturally occurring protein with immunomodulatory, antiproliferative and antiviral properties. Interferon alpha plays a critical role in maintaining the balance of the immune system, and is produced normally by the body in very low concentrations compared to traditional injectable interferon therapy which tries to achieve sufficient concentration to reach the disease site. If interferon alpha is inoculated directly into the bloodstream, very high doses--literally millions of international units (IU)--are required to assure that sufficient amounts reach the diseased tissue. High-dose injectable interferon is FDA approved as a treatment for various chronic disorders, particularly cancer, hepatitis B and hepatitis C. Such approaches have proven effective in some instances, but high-dose systemic interferon alpha therapy often has the disadvantage of high cost and severe side effects. Many infectious agents which enter the body through inhalation or ingestion induce low concentrations of interferon in the nasal or pharyngeal secretions. We feel our low-dose concentration and route of administration effectively mimics nature, with the interferon attracted by receptors in the oral mucosal surface, stimulating the immune system. Our research supports this belief.		Our research indicates that our low-dose oral interferon is proving to be effective as a therapeutic, does not require a needle and syringe, does not cause severe adverse effects, can be stored at room temperature and is less expensive than injectable interferon alpha. "Amarillo Biosciences' technology involves trying to do something that we think is perfectly natural at the oral mucosal surface, which is where our bodies often produce interferon. "What normally happens to us, if we are sick with hepatitis, for example, is that we are treated with 3 million to 10 million international units of interferon injected three times a week. I believe that people don't make that much interferon in a lifetime. It is like asking, do I give five pounds of insulin to somebody because I can make it in a lab? No, you give insulin at the level produced in the body. Our technology doses interferon at the same low concentration normally produced in the body. We recognize that interferon is produced in the nasal secretions, and trickles down the throat. We think it hits receptors there that stimulate the immune system. A considerable amount of data supports our position that oral interferon stimulates a systemic effect. "We are a leader in research with low-dose oral interferon, and we will continue our work with this concept, until low-dose oral interferon is accepted in the field of interferon therapies."
. . .For more facts on our lead product candidate - Low Dose Oral Interferon Alpha. >>> . . For a compendium of publications on the use of low dose interferon in humans and animals. >>> .